RATIONALE: Deep learning is a powerful tool that may allow for improved outcome prediction. OBJECTIVES: To determine if deep learning, specifically convolutional neural network (CNN) analysis, could detect and stage chronic obstructive pulmonary disease (COPD) and predict acute respiratory disease (ARD) events and mortality in smokers. METHODS: A CNN was trained using computed tomography scans from 7,983 COPDGene participants and evaluated using 1,000 nonoverlapping COPDGene participants and 1,672 ECLIPSE participants. Logistic regression (C statistic and the Hosmer-Lemeshow test) was used to assess COPD diagnosis and ARD prediction. Cox regression (C index and the Greenwood-Nam-D'Agnostino test) was used to assess mortality. MEASUREMENTS AND MAIN RESULTS: In COPDGene, the C statistic for the detection of COPD was 0.856. A total of 51.1% of participants in COPDGene were accurately staged and 74.95% were within one stage. In ECLIPSE, 29.4% were accurately staged and 74.6% were within one stage. In COPDGene and ECLIPSE, the C statistics for ARD events were 0.64 and 0.55, respectively, and the Hosmer-Lemeshow P values were 0.502 and 0.380, respectively, suggesting no evidence of poor calibration. In COPDGene and ECLIPSE, CNN predicted mortality with fair discrimination (C indices, 0.72 and 0.60, respectively), and without evidence of poor calibration (Greenwood-Nam-D'Agnostino P values, 0.307 and 0.331, respectively). CONCLUSIONS: A deep-learning approach that uses only computed tomography imaging data can identify those smokers who have COPD and predict who are most likely to have ARD events and those with the highest mortality. At a population level CNN analysis may be a powerful tool for risk assessment.
RATIONALE: Deep learning is a powerful tool that may allow for improved outcome prediction. OBJECTIVES: To determine if deep learning, specifically convolutional neural network (CNN) analysis, could detect and stage chronic obstructive pulmonary disease (COPD) and predict acute respiratory disease (ARD) events and mortality in smokers. METHODS: A CNN was trained using computed tomography scans from 7,983 COPDGeneparticipants and evaluated using 1,000 nonoverlapping COPDGeneparticipants and 1,672 ECLIPSE participants. Logistic regression (C statistic and the Hosmer-Lemeshow test) was used to assess COPD diagnosis and ARD prediction. Cox regression (C index and the Greenwood-Nam-D'Agnostino test) was used to assess mortality. MEASUREMENTS AND MAIN RESULTS: In COPDGene, the C statistic for the detection of COPD was 0.856. A total of 51.1% of participants in COPDGene were accurately staged and 74.95% were within one stage. In ECLIPSE, 29.4% were accurately staged and 74.6% were within one stage. In COPDGene and ECLIPSE, the C statistics for ARD events were 0.64 and 0.55, respectively, and the Hosmer-Lemeshow P values were 0.502 and 0.380, respectively, suggesting no evidence of poor calibration. In COPDGene and ECLIPSE, CNN predicted mortality with fair discrimination (C indices, 0.72 and 0.60, respectively), and without evidence of poor calibration (Greenwood-Nam-D'Agnostino P values, 0.307 and 0.331, respectively). CONCLUSIONS: A deep-learning approach that uses only computed tomography imaging data can identify those smokers who have COPD and predict who are most likely to have ARD events and those with the highest mortality. At a population level CNN analysis may be a powerful tool for risk assessment.
Authors: Harvey O Coxson; Brendan Quiney; Don D Sin; Li Xing; Annette M McWilliams; John R Mayo; Stephen Lam Journal: Am J Respir Crit Care Med Date: 2008-02-28 Impact factor: 21.405
Authors: Raúl San José Estépar; Gregory L Kinney; Jennifer L Black-Shinn; Russell P Bowler; Gordon L Kindlmann; James C Ross; Ron Kikinis; Meilan K Han; Carolyn E Come; Alejandro A Diaz; Michael H Cho; Craig P Hersh; Joyce D Schroeder; John J Reilly; David A Lynch; James D Crapo; J Michael Wells; Mark T Dransfield; John E Hokanson; George R Washko Journal: Am J Respir Crit Care Med Date: 2013-07-15 Impact factor: 21.405
Authors: Miguel-Angel Martínez-García; David de la Rosa Carrillo; Juan-Jose Soler-Cataluña; Yolanda Donat-Sanz; Pablo Catalán Serra; Marco Agramunt Lerma; Javier Ballestín; Irene Valero Sánchez; Maria Jose Selma Ferrer; Anna Roma Dalfo; Montserrat Bertomeu Valdecillos Journal: Am J Respir Crit Care Med Date: 2013-04-15 Impact factor: 21.405
Authors: Brian C Sauer; Barbara E Jones; Gary Globe; Jianwei Leng; Chao-Chin Lu; Tao He; Chia-Chen Teng; Patrick Sullivan; Qing Zeng Journal: EGEMS (Wash DC) Date: 2016-06-01
Authors: Matthew Moll; Dandi Qiao; Elizabeth A Regan; Gary M Hunninghake; Barry J Make; Ruth Tal-Singer; Michael J McGeachie; Peter J Castaldi; Raul San Jose Estepar; George R Washko; James M Wells; David LaFon; Matthew Strand; Russell P Bowler; MeiLan K Han; Jorgen Vestbo; Bartolome Celli; Peter Calverley; James Crapo; Edwin K Silverman; Brian D Hobbs; Michael H Cho Journal: Chest Date: 2020-04-27 Impact factor: 9.410
Authors: Wassim W Labaki; Lucas M Kimmig; Gökhan M Mutlu; MeiLan K Han; Surya P Bhatt Journal: Am J Respir Crit Care Med Date: 2019-06-15 Impact factor: 21.405
Authors: Paul A Reyfman; George R Washko; Mark T Dransfield; Avrum Spira; MeiLan K Han; Ravi Kalhan Journal: Am J Respir Crit Care Med Date: 2018-08-15 Impact factor: 21.405